Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies. The company has market cap of $8.22 billion. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.
Analysts expect Cincinnati Bell Inc. (NYSE:CBB) to report $0.04 EPS on February, 21.They anticipate $0.03 EPS change or 300.00% from last quarter’s $0.01 EPS. CBB’s profit would be $1.69 million giving it 111.56 P/E if the $0.04 EPS is correct. After having $0.03 EPS previously, Cincinnati Bell Inc.’s analysts see 33.33% EPS growth. The stock increased 0.84% or $0.149 during the last trading session, reaching $17.849. About 80,600 shares traded. Cincinnati Bell Inc. (NYSE:CBB) has declined 3.61% since January 18, 2017 and is downtrending. It has underperformed by 20.31% the S&P500.
Peconic Partners Llc holds 4.12% of its portfolio in Juno Therapeutics, Inc. for 570,000 shares. Sib Llc owns 100,000 shares or 3.22% of their US portfolio. Moreover, Cormorant Asset Management Llc has 2.97% invested in the company for 375,000 shares. The Switzerland-based Bb Biotech Ag has invested 2.55% in the stock. Iguana Healthcare Management Llc, a New York-based fund reported 75,000 shares.
The stock increased 3.96% or $2.74 during the last trading session, reaching $71.99. About 4.97M shares traded or 88.58% up from the average. Juno Therapeutics, Inc. (JUNO) has declined 39.85% since January 18, 2017 and is downtrending. It has underperformed by 56.55% the S&P500.
Analysts await Juno Therapeutics, Inc. (NASDAQ:JUNO) to report earnings on March, 7. They expect $-1.02 earnings per share, down 54.55% or $0.36 from last year’s $-0.66 per share. After $-1.12 actual earnings per share reported by Juno Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.93% EPS growth.
Cincinnati Bell Inc., together with its subsidiaries, provides diversified telecommunications and technology services to residential and business clients in the United States. The company has market cap of $752.97 million. The Entertainment and Communications segment offers data services, including high-speed Internet access, data transport, and interconnection services, as well as metro-Ethernet products; and voice local services, such as Fioptics voice lines, voice over Internet protocol, long distance, digital trunking, switched access, caller identification, voicemail, call waiting, and call return. It has a 19.01 P/E ratio. It also provides video services comprising entertainment channels, including digital music, local, movie, and sports programming, high-definition channels, parental controls, HD DVR, and video on-demand.
Among 3 analysts covering Cincinnati Bell (NYSE:CBB), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Cincinnati Bell had 6 analyst reports since August 21, 2015 according to SRatingsIntel. On Thursday, October 6 the stock rating was upgraded by Gabelli to “Buy”. On Tuesday, December 6 the stock rating was downgraded by Raymond James to “Underperform”. Gabelli maintained Cincinnati Bell Inc. (NYSE:CBB) on Friday, August 21 with “Buy” rating. The rating was downgraded by Gabelli to “Hold” on Tuesday, August 8. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, November 30.
Investors sentiment increased to Infinity in 2017 Q3. Its up Infinity, from 0 in 2017Q2. It increased, as 0 investors sold Cincinnati Bell Inc. shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 504,860 shares or 46646.30% more from 1,080 shares in 2017Q2 were reported. Alphamark Advsr Limited holds 1,080 shares. 251,350 were accumulated by Tocqueville Asset Management Limited Partnership.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.